Literature DB >> 7387775

Elevation of serum high density lipoprotein cholesterol by rowachol, a proprietary mixture of six pure monoterpenes.

G D Bell, J P Bradshaw, A Burgess, W Ellis, J Hatton, A Middleton, B Middleton, T Orchard, D A White.   

Abstract

Rowachol, a proprietary choleretic containing 6 pure monoterpenes markedly elevates serum HDL cholesterol (SHDL-C) concentrations in man. The concentration of SHDL-C showed a progressive increase in 16 patients treated with 6-9 capsules of Rowachol daily for periods of 2-28 weeks. There was no accompanying significant change in the concentrations of serum total cholesterol or triglyceride. In view of the significant inverse relationship between SHDL-C concentration and the risk of developing ischaemic heart disease, it is suggested that Rowachol and possibly other terpenes merit further investigation as possible therapeutic agents in the prevention and treatment of atheroma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7387775     DOI: 10.1016/0021-9150(80)90197-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

1.  Inhibition of human lecithin cholesterol acyltransferase by monoterpenes.

Authors:  R V Cooney; J Nemhauser; R J Morin
Journal:  Lipids       Date:  1984-05       Impact factor: 1.880

2.  Administration of a terpene mixture inhibits cholesterol nucleation in bile from patients with cholesterol gallstones.

Authors:  K von Bergmann; A Beck; C Engel; O Leiss
Journal:  Klin Wochenschr       Date:  1987-05-15

3.  Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers.

Authors:  O Leiss; K von Bergmann
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.